Kelly J. Clark | |
---|---|
Occupation(s) | Physician, psychiatrist |
Academic background | |
Education | Coe College (BA) Fuqua School of Business (MBA) |
Alma mater | University of Wisconsin (MD) |
Academic work | |
Institutions | University of Wisconsin-Milwaukee Medical College of Wisconsin University of Massachusetts Virginia Tech |
Main interests | Substance abuse disorder Addiction medicine Addiction psychiatry |
Kelly J. Clark is an American physician and psychiatrist known for her work in the fields of substance use disorder,addiction medicine,and addiction psychiatry. [1]
Clark graduated cum laude from Coe College with a BA in Psychology as a member of the Phi Beta Kappa honor society. [1] [2] [3] She received her MD from the University of Wisconsin in 1989. [1] [2] [3] She also earned an MBA with a certificate in Health Sector Management from Duke University's Fuqua School of Business in 2007. [1] [2] [3]
At the start of her career,Clark completed psychiatric residencies at the University of Wisconsin-Milwaukee from 1990 to 1992 and the Medical College of Wisconsin from 1992 to 1994. [1] [2] She has been a member of the American Psychiatric Association since 1988,eventually becoming a distinguished fellow in 2011 and a member of the APA's Integrated Care Work group from 2012 to 2017. [1] [3] [4]
From 1996 to 2004,she served as Assistant Professor of Psychiatry at the University of Massachusetts. [2] [3] From 2009 to 2012,she served as Medical Director for Behavioral Health at Capital District Physician's Health Plan. [3] [5] She was a founding faculty member of the Virginia Tech Carilion School of Medicine in 2010,where she taught until 2016. [1] [3]
From 2012 to 2014,she served as Chief Medical Officer of Behavioral Health Group. [3] [6] From 2014 to 2015,she was Chief Medical Officer of CleanSlate Centers [3] [7] [8] and from 2014 to 2018,she was Medical Director of CVS Caremark. [3] [8] [9] In 2018,she founded and became President of Addiction Crisis Solutions, [10] [11] [12] [3] and she also joined the board of drug disposal company DisposeRX. [13] [3]
In 2017,she was elected President of the American Society of Addiction Medicine (ASAM). [10] [11] [14] [13] [3] [ excessive citations ] She served in this role until 2019. [3] [4]
She is also the current vice-chair of ASAM's COVID-19 Task Force. [2]
Clark's areas of focus are addictive disease,behavioral health care,and health care payment reform. [1] [10] [11] She has advocated the use of FDA-approved drugs to treat drug and alcohol addiction as a chronic brain disease. [15] [16] However,she acknowledges that there are challenges patients face in obtaining access to methadone,naltrexone,and buprenorphine,the 3 FDA-approved medications for treating opioid addiction. [17]
She has helped develop guidelines for dealing with opioid addiction in the workplace, [18] medication-assisted treatment for opioid addiction, [19] [20] and drug testing. [21]
She has served as an expert on the opioid crisis to government officials such as the United States Presidential Opioid and Drug Abuse Commission,the Food and Drug Administration (FDA),the Department of Justice (DOJ),the Substance Abuse and Mental Health Services Administration (SAMSHA),and the Office of the Comptroller General. [2] [10] [11] [13]
She has also served as a medical expert witness in multiple legal cases,including Federal District Court cases involving health insurance fraud,drug trafficking and human trafficking. [22] [23] [24] [25] [26] [ excessive citations ]
Naloxone,sold under the brand name Narcan among others,is a medication used to reverse or reduce the effects of opioids. It is commonly used to counter decreased breathing in opioid overdose. Effects begin within two minutes when given intravenously,and within five minutes when injected into a muscle. The medicine can also be administered by spraying it into a person's nose. Naloxone commonly blocks the effects of opioids for 30 to 90 minutes. Multiple doses may be required,as the duration of action of some opioids is greater than that of naloxone. Emergency medical services data from Massachusetts found that 93.5% of people given naloxone survived their overdose.
Hydromorphone,also known as dihydromorphinone,and sold under the brand name Dilaudid among others,is an opioid used to treat moderate to severe pain. Typically,long-term use is only recommended for pain due to cancer. It may be used by mouth or by injection into a vein,muscle,or under the skin. Effects generally begin within half an hour and last for up to five hours.
A prescription drug is a pharmaceutical drug that is only permitted to be dispensed to those with a medical prescription. In contrast,over-the-counter drugs can be obtained without a prescription. The reason for this difference in substance control is the potential scope of misuse,from drug abuse to practicing medicine without a license and without sufficient education. Different jurisdictions have different definitions of what constitutes a prescription drug.
Oxycodone/paracetamol,sold under the brand name Percocet among others,is a fixed-dose combination of the opioid oxycodone with paracetamol (acetaminophen),used to treat moderate to severe pain.
Opioid use disorder (OUD) is a substance use disorder characterized by cravings for opioids,continued use despite physical and/or psychological deterioration,increased tolerance with use,and withdrawal symptoms after discontinuing opioids. Opioid withdrawal symptoms include nausea,muscle aches,diarrhea,trouble sleeping,agitation,and a low mood. Addiction and dependence are important components of OUD.
Buprenorphine is an opioid used to treat opioid use disorder,acute pain,and chronic pain. It can be used under the tongue (sublingual),in the cheek (buccal),by injection,as a skin patch (transdermal),or as an implant. For opioid use disorder,it is typically started when withdrawal symptoms have begun and for the first two days of treatment under direct observation of a health-care provider. In the United States,the combination formulation of buprenorphine/naloxone (Suboxone) is usually prescribed to discourage misuse by injection. Maximum pain relief is generally within an hour with effects up to 24 hours. Buprenorphine affects different types of opioid receptors in different ways. Depending on the type of receptor,it may be an agonist,partial agonist,or antagonist. In the treatment of opioid use disorder buprenorphine is an agonist/antagonist,meaning that it relieves withdrawal symptoms from other opioids and induces some euphoria,but also blocks the ability for many other opioids,including heroin,to cause an effect. Unlike full agonists like heroin or methadone,buprenorphine has a ceiling effect,such that taking more medicine will not increase the effects of the drug.
Sufentanil,sold under the brand names Dsuvia and Sufenta,is a synthetic opioid analgesic drug approximately 5 to 10 times as potent as its parent drug,fentanyl,and 500 times as potent as morphine. Structurally,sufentanil differs from fentanyl through the addition of a methoxymethyl group on the piperidine ring,and the replacement of the phenyl ring by thiophene. Sufentanil first was synthesized at Janssen Pharmaceutica in 1974.
Ketorolac,sold under the brand names Toradol,and Biorolac among others,is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain. Specifically it is recommended for moderate to severe pain. Recommended duration of treatment is less than six days. It is used by mouth,by nose,by injection into a vein or muscle,and as eye drops. Effects begin within an hour and last for up to eight hours.
Substance dependence,also known as drug dependence,is a biopsychological situation whereby an individual's functionality is dependent on the necessitated re-consumption of a psychoactive substance because of an adaptive state that has developed within the individual from psychoactive substance consumption that results in the experience of withdrawal and that necessitates the re-consumption of the drug. A drug addiction,a distinct concept from substance dependence,is defined as compulsive,out-of-control drug use,despite negative consequences. An addictive drug is a drug which is both rewarding and reinforcing. ΔFosB,a gene transcription factor,is now known to be a critical component and common factor in the development of virtually all forms of behavioral and drug addictions,but not dependence.
Stuart Gitlow is a general,forensic,and addiction psychiatrist and Past President of the American Society of Addiction Medicine.
Nalmefene is an opioid antagonist medication used in the management of opioid overdose and alcohol dependence. It is taken by mouth.
Hydrocodone/paracetamol is the combination of the pain medications hydrocodone and paracetamol (acetaminophen). It is used to treat moderate to severe pain. It is taken by mouth. Recreational use is common in the United States.
The Drug Addiction Treatment Act of 2000,Title XXXV,Section 3502 of the Children's Health Act,permits physicians who meet certain qualifications to treat opioid addiction with Schedule III,IV,and V narcotic medications that have been specifically approved by the Food and Drug Administration for that indication.
An opioid overdose is toxicity due to excessive consumption of opioids,such as morphine,codeine,heroin,fentanyl,tramadol,and methadone. This preventable pathology can be fatal if it leads to respiratory depression,a lethal condition that can cause hypoxia from slow and shallow breathing. Other symptoms include small pupils,and unconsciousness,however its onset can depend on the method of ingestion,the dosage and individual risk factors. Although there were over 110,000 deaths in 2017 due to opioids,individuals who survived also faced adverse complications,including permanent brain damage.
Mark S. Gold is an American physician,professor,author,and researcher on the effects of opioids,cocaine,tobacco,and other drugs as well as food on the brain and behavior. He is married to Janice Finn Gold.
Oliceridine,sold under the brand name Olinvyk,is an opioid medication that is used for the treatment of moderate to severe acute pain in adults. It is given by intravenous (IV) injection.
Buprenorphine/naloxone,sold under the brand name Suboxone among others,is a fixed-dose combination medication that includes buprenorphine and naloxone. It is used to treat opioid use disorder,and reduces the mortality of opioid use disorder by 50%. It relieves cravings to use and withdrawal symptoms. Buprenorphine/naloxone is available for use in two different forms,under the tongue or in the cheek.
In the United States,the opioid epidemic is an extensive ongoing overuse of opioid medications,both from medical prescriptions and illegal sources. The epidemic began in the United States in the late 1990s,according to the Centers for Disease Control and Prevention (CDC),when opioids were increasingly prescribed for pain management,resulting in a rise in overall opioid use throughout subsequent years. The great majority of Americans who use prescription opioids do not believe that they are misusing them.
David R. Gastfriend is an American psychiatrist,internationally recognized addiction treatment researcher,the former Chief Executive Officer of the Treatment Research Institute (TRI),and current Chief Medical Officer of DynamiCare Health.
Prescription drug addiction is the chronic,repeated use of a prescription drug in ways other than prescribed for,including using someone else’s prescription. A prescription drug is a pharmaceutical drug that may not be dispensed without a legal medical prescription. Drugs in this category are supervised due to their potential for misuse and Substance use disorder. The classes of medications most commonly abused are opioids,central nervous system (CNS) depressants and central nervous stimulants. In particular,prescription opioid is most commonly abused in the form of prescription analgesics.